These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24022094)

  • 1. Peginterferon plus Chinese herbal therapy is associated with a higher virological response than only peginterferon therapy in chronic hepatitis C.
    Cheng D; Liu E; Li Y; Liu R; Bai L; Chen Y; Wang Y; Chu Y; Wu M; Cheng G; Zhao S
    Eur J Clin Microbiol Infect Dis; 2014 Mar; 33(3):433-8. PubMed ID: 24022094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of peginterferon and interferon in treating Chinese patients with chronic hepatitis C.
    Zhao S; Liu E; Yu H; Yang H; Xun M; Xue X; Song J; Xu K; Chu Y
    Hepatogastroenterology; 2008; 55(84):1047-54. PubMed ID: 18705326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with peginterferon versus interferon in Chinese patients with chronic hepatitis C.
    Zhao S; Liu E; Wei K; Wang Y; Li Y; Huang B; Chen Y; Yang P
    Eur J Clin Microbiol Infect Dis; 2011 Jan; 30(1):51-7. PubMed ID: 20827497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
    Zhao S; Liu E; Chen P; Cheng D; Lu S; Yu Q; Wang Y; Wei K; Yang P
    Clin Ther; 2010 Aug; 32(9):1565-77. PubMed ID: 20974315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peginterferon and Chinese herbs exert a combinatorial effect in HBeAg-positive chronic hepatitis B.
    An Y; Gao S; Cheng D; Wang X; Bai L; Liu E; Chu Y; Zhao S
    J Infect Dev Ctries; 2016 Apr; 10(4):369-76. PubMed ID: 27130998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis: pegylated interferon α-2a achieves higher early virological responses than α-2b in chronic hepatitis C.
    Romero-Gómez M; Planas R; Ampuero J; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Turnes J
    Aliment Pharmacol Ther; 2013 Jun; 37(11):1065-73. PubMed ID: 23581537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C.
    Zhao SH; Chu YL; Cheng DX; Waqar AB; Yu Q; Yang PH; Xue X; Yang HJ; Liu EQ
    Int J Clin Pract; 2009 Sep; 63(9):1334-9. PubMed ID: 19691617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
    Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008516. PubMed ID: 22972122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C.
    García-Samaniego J; Romero M; Granados R; Alemán R; Jorge Juan M; Suárez D; Pérez R; Castellano G; González-Portela C
    World J Gastroenterol; 2013 Mar; 19(12):1943-52. PubMed ID: 23569340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials.
    Awad T; Thorlund K; Hauser G; Stimac D; Mabrouk M; Gluud C
    Hepatology; 2010 Apr; 51(4):1176-84. PubMed ID: 20187106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis.
    Kim AI; Dorn A; Bouajram R; Saab S
    HIV Med; 2007 Jul; 8(5):312-21. PubMed ID: 17561878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
    Marcellin P; Craxi A; Brandao-Mello CE; Di Bisceglie AM; Andreone P; Freilich B; Rajender Reddy K; Olveira Martín A; Teuber G; Messinger D; Hooper G; Wat C; Tatsch F; Jensen DM
    J Clin Gastroenterol; 2013 Oct; 47(9):786-93. PubMed ID: 23442834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.
    Fernández-Rodríguez CM; Morillas RM; Masnou H; Navarro JM; Bárcena R; González JM; Martín-Martín L; Poyato A; Miquel-Planas M; Jorquera F; Casanovas T; Salmerón J; Calleja JL; Solà R; Alonso S; Planas R; Romero-Gomez M
    Gastroenterol Hepatol; 2014 Jan; 37(1):1-8. PubMed ID: 24360571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The virological response in prolonged therapy of chronic hepatitis C with low-dose peginterferon alpha-2a].
    Zhou JY; Zhou DF; Xing WL; Zhao CY; Zhen Z
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Apr; 24(2):142-4. PubMed ID: 21110439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-Analysis of Combination Therapy of Chinese Herbs Plus Interferon and Ribavirin in Patients with Chronic Hepatitis C.
    Wang J; Xin S; Jin X; Cheng Y; Yan T; Qing S; Ding N; Zhao P
    Med Sci Monit; 2016 May; 22():1817-26. PubMed ID: 27237628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virological response of Tunisians patients treated by peginterferon plus ribavirin for chronic hepatitis C: a preliminary study.
    Belhadj N; Houissa F; Elloumi H; Ouakaa A; Gargouri D; Romani M; Kilani A; Kochlef A; Kharrat J; Ghorbel A
    Tunis Med; 2008 Apr; 86(4):341-5. PubMed ID: 19476135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.